May 5, 2016 writer

TSO3 announces the Results of the Votes from its Annual and Special Meeting of the Shareholders

Québec City, May 5, 2016 – TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated March 22, 2016, were elected as directors of TSO3 Inc. In addition, all other proposals submitted by management were approved.

Election of Directors

The shareholders were asked to provide their decision via a vote by proxy as part of TSO3Annual General Meeting of Shareholders, held on May 4, 2016 in Québec. The detailed results of the vote are set out below.



Name

Votes for

% for
Votes against
% against
Withheld/
Abstain

% withheld
Germain Carrière
35,429,726
95.17
0
0
1,799,908
4.83
Pierre Désy
36,463,106 97.94 0 0
766,528
2.06
Jean Lamarre
35,388,316 95.05 0 0
1,841,318
4.95
Claude Michaud
35,790,756 96.14 0 0
1,438,878
3.86
Jean-Pierre Robert
36,840,666 98.96 0 0
388,968
1.04
Richard M. Rumble
37,189,728 99.89 0 0
39,906
0.11
Steve West
37,182,448 99.87 0 0
47,186
0.13
­Other Proposals

 

Appointment of Independent Auditors
 

41,759,965

 

99.95


0

0

21,035

0.05
Adoption of the 2016 Stock Incentive Plan
 

24,293,413

 

65.25

 

12,936,221


34.75

0

0.00
Increase the number of the Stock Option Plan
 

29,928,651

 

80.39

 

7,300,983


19.61

0

0.00
Amendments to articles
36,266,128 97.41 963,506
2.59
0
0.00

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 4, 2016, will be filed on SEDAR (www.sedar.com) under the name TSO3.

About TSO3

Founded in 1998, TSO3 is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO3 designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the company’s web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3’s sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful. 

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Back to Posts